Pharm Exec8 小时
FDA Approves Roche’s Evrysdi for Spinal Muscular Atrophy
Evrysdi is a non-invasive, disease-modifying option that can be swallowed whole or dispersed in water for patients with ...
First Participant Randomized in AskBio European Phase 2 Gene Therapy Trial for Congestive ...
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms GenePHIT is a clinical ...
Asklepios BioPharmaceutical, Inc. (AskBio): First Participant Randomized in AskBio European ...
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) ...
PipelineReview.com18 小时
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular ...
SOUTH SAN FRANCISCO, CA, USA I 12, 2025 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug ...